论文部分内容阅读
目的观察抵克立得、阿斯匹林加潘生丁预防急性脑梗塞复发的疗效。方法抵克立得组８２例，阿斯匹林加潘生丁组１００例，观察期分别为１４．８个月和１６．６个月。结果治疗１年后抵克立得组复发８例（９．７５％），阿斯匹林加潘生丁组复发３３例（３３％），前者在应用９、１２个月后预防急性脑梗塞复发数显著优于阿斯匹林加潘生丁组（Ｐ＜０．０５）。结论抵克立得是预防急性脑梗塞复发较好的药物
Objective To observe the curative effect of Tacrolimus and aspirin plus dipyridamole in the prevention of recurrent acute cerebral infarction. Methods Eighty-two patients in the treatment group and 100 aspirin plus dipyridamole groups were observed for 14.8 months and 16.6 months respectively. Results One year after treatment, 8 cases (9.75%) were relapsed in the clidiazide group and 33 cases (33%) in the aspirin plus dipyridamole group. The former prevented the recurrence of acute cerebral infarction after 9 and 12 months Significantly better than aspirin plus dipyridamole group (P <0.05). Conclusion Tieke Li is a good drug to prevent recurrence of acute cerebral infarction